Andrew Saykin's, PsyD research program focuses on precision medicine for the early detection of Alzheimer’s disease and related dementias. His laboratory utilizes the integration of advanced multimodal high throughput neuroimaging, cognitive neuroscience, and multiple “omics” data, such as gene and protein/metabolite networks, to identify novel biomarkers of disease mechanisms and potential therapeutic targets of disease. Saykin’s research also encompasses the study of cognitive/memory deficits as they relate to cancer, traumatic brain injury, temporal lobe epilepsy, schizophrenia and other brain diseases.
This information is integrated with advanced analytics that utilize multi-omics datasets, such as transcriptomics, metabolomics, proteomics, and genomics, in a systems biology approach that simulates complex biological systems and interactions. In unison, these complex tools aid in the identification of biomarkers for early risk, which are important for characterizing pathophysiology, identifying novel targets for therapeutic development and assessing the response to treatment.